

### LISTING OF THE CLAIMS

The following listing of the claims replaces all prior versions and listings of claims for this application. Within this listing of the claims, claims 26 and 30-60 are pending; claims 34 and 36-44 have been withdrawn from consideration as drawn to a non-elected invention or species; claims 48, 49, and 55 are currently amended; and claims 59 and 60 are new. Amendments to the claims are indicated with a strikethrough for deleted subject matter and underlining for new recitations.

1.- 25. **(Cancelled)**

26. **(Previously presented)** A dermatological formulation comprising a physiologically acceptable carrier and an effective amount of one or more plant extracts that inhibit the activity of at least one extracellular protease selected from the group of: matrix metalloprotease-1 (MMP-1), matrix metalloprotease-2 (MMP-2), matrix metalloprotease-3 (MMP-3), matrix metalloprotease-9 (MMP-9) and human leukocyte elastase (HLE), wherein said one or more plant extracts modulates one or more cellular activities in skin cells, each of said one or more plant extracts derived by solvent extraction of plant material from *Capsicum annuum* L., *Chenopodium quinoa*, *Geranium x cantabrigiense*, *Juniperus communis* L., *Melilotus alba* Medik., *Pastinaca sativa* L., *Potentilla anserina* L., *Rhus typhina* L., *Tropaeolum majus* L., *x Triticosecale* spp. or *Zea mays* L, wherein said plant material from *Chenopodium quinoa* comprises *Chenopodium quinoa* seeds.

27-29. **(Cancelled)**

30. **(Previously presented)** The dermatological formulation according to claim 26, wherein said one or more cellular activities in skin cells are selected from the group of: attenuating endothelial cell migration; increasing collagen production; inhibiting ultraviolet-induced extracellular protease activity and inhibiting dermal contraction.

31. **(Previously presented)** The dermatological formulation according to claim 26, wherein said solvent is an aqueous solvent, an alcoholic solvent, or a combination thereof.

32. **(Previously presented)** The dermatological formulation according to claim 31, wherein said alcoholic solvent is ethanol or a glycol.

33. **(Previously presented)** The dermatological formulation according to claim 32, wherein said glycol is butylene glycol or propylene glycol.

34. **(Withdrawn)** The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Capsicum annuum L.*

35. **(Previously presented)** The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Chenopodium quinoa*.

36. **(Withdrawn)** The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Geranium x cantabrigiense*.

37. **(Withdrawn)** The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Juniperus communis L.*

38. **(Withdrawn)** The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Melilotus alba Medik.*

39. **(Withdrawn)** The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Pastinaca sativa L.*

40. **(Withdrawn)** The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Potentilla anserina L.*

41. **(Withdrawn)** The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Rhus typhina L.*

42. **(Withdrawn)** The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Tropaeolum majus L.*

43. **(Withdrawn)** The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *x Triticosecale spp.*

44. **(Withdrawn)** The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Zea mays L.*

45. **(Previously presented)** The dermatological formulation according to claim 26, further comprising a moisturising agent.

46. **(Previously presented)** The dermatological formulation according to claim 26, wherein said formulation is formulated for topical or oral administration.

47. **(Previously presented)** A method for improving the appearance of skin in a subject comprising administering the dermatological formulation according to claim 26 to said subject, wherein said improving the appearance of skin comprises decreasing the appearance of wrinkles.

48. **(Currently amended)** A method for attenuating or ~~preventing~~ delaying the onset of skin ageing in a subject comprising administering the dermatological formulation according to claim 26 to said subject, wherein said skin ageing comprises formation of wrinkles.

49. **(Currently amended)** A method for treating or ~~preventing~~ delaying the onset of a dermatological condition in a subject comprising administering the dermatological formulation according to claim 26 to said subject, wherein said dermatological condition comprises skin wrinkling.

50. **(Previously presented)** The method according to claim 49, wherein said dermatological condition further comprises loss of skin elasticity, redness, and/or inflammation.

51. **(Previously presented)** The method according to claim 47, wherein said dermatological formulation is administered orally or topically.

52. **(Previously presented)** The method according to claim 48, wherein said dermatological formulation is administered orally or topically.

53. **(Previously presented)** The method according to claim 49, wherein said dermatological formulation is administered orally or topically.

54. **(Previously presented)** The method according to claim 47, wherein said improving the appearance of skin further comprises decreasing loss of skin elasticity, redness, and/or inflammation.

55. **(Currently amended)** The method according to claim 48, wherein said ~~attenuating~~ skin ageing further comprises attenuating loss of skin elasticity, redness, and/or inflammation.

56. **(Previously presented)** A method for delaying appearance or progression of visible effects of skin ageing in a subject comprising administering the dermatological formulation according to claim 26 to said subject, wherein said visible effects comprise skin wrinkling.

57. **(Previously presented)** The method according to claim 56, wherein said visible effects further comprise loss of skin elasticity, redness, and/or inflammation.

58. **(Previously presented)** The method according to claim 56, wherein said dermatological formulation is administered topically.

59. **(New)** A method of increasing collagen production in skin of a subject comprising administering the dermatological formulation according to claim 26 to said subject.

60. **(New)** The method according to claim 59, wherein said dermatological formulation is administered topically.